for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott India Limited

ABOT.NS

Latest Trade

15,399.05INR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

12,186.55

 - 

18,679.75

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
15,399.00
Open
--
Volume
--
3M AVG Volume
0.20
Today's High
--
Today's Low
--
52 Week High
18,679.75
52 Week Low
12,186.55
Shares Out (MIL)
21.25
Market Cap (MIL)
327,219.10
Forward P/E
45.31
Dividend (Yield %)
0.69

Latest Developments

More

Abbott India Sept-Quarter Net Profit Rises

Abbott India Ltd Recommended Payment Of Final Dividend Of 107 Rupees Per Share For Year Ended March 31

Abbott India Approves Appointment Of Anil Joseph As Managing Director

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott India Limited

Abbott India Limited is a healthcare company engaged in pharmaceuticals business. The Company has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Its business operations are divided into four business divisions: Women's Health & Gastrointestine, Gastroenterology and Hepatic Care; Specialty Care; GenNext & Vaccines, and Consumer Care. Women's Health & Gastrointestine, Gastroenterology and Hepatic Care division has a mix of global and local brands present in the pregnancy, constipation and liver diseases segments. The Specialty Care division consists of a range of products in the treatment of central nervous system and metabolic disorders. The GenNext division focuses on several therapy areas, including pain management, vitamins and pregnancy. Its vaccines include Enteroshield (typhoid vaccine) and Rotasure (rotavirus diarrhea vaccine). The Consumer Care division is present in the over the counter antacid segment.

Industry

Biotechnology & Drugs

Contact Info

3-4 Corporate Park

Sion-Trombay Road, Chembur

400051

India

+91.22.38162000

http://www.abbott.co.in/

Executive Leadership

Munir Ahmed Shaikh

Non-Executive Independent Chairman of the Board

Rajiv Sonalker

Chief Financial Officer, Additional Whole Time Director

Krupa Anandpara

Compliance Officer, Company Secretary

Ambati Venu

Vice President - Established Pharmaceutical Products, Additional Director

Anil Joseph

Managing Director, Additional Director

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

33.0K

2019

36.8K

2020

40.9K

2021(E)

43.9K
EPS (INR)

2018

188.810

2019

211.930

2020

279.040

2021(E)

330.270
Price To Earnings (TTM)
49.67
Price To Sales (TTM)
7.87
Price To Book (MRQ)
14.46
Price To Cash Flow (TTM)
45.64
Total Debt To Equity (MRQ)
7.34
LT Debt To Equity (MRQ)
5.79
Return on Investment (TTM)
27.81
Return on Equity (TTM)
19.79

Latest News

Latest News

BRIEF-Abbott India Ltd Recommended Payment Of Final Dividend Of 107 Rupees Per Share For Year Ended March 31

* ABBOTT INDIA LTD - RECOMMENDED PAYMENT OF FINAL DIVIDEND OF 107 RUPEES PER SHARE AND SPECIAL DIVIDEND OF 143 RUPEES PER SHARE FOR YEAR ENDED MARCH 31 Source text for Eikon: Further company coverage:

BRIEF-Abbott India Approves Appointment Of Anil Joseph As Managing Director

* ABBOTT INDIA LTD SAYS APPROVED APPOINTMENT OF ANIL JOSEPH AS MANAGING DIRECTOR OF COMPANY Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Abbott India Ambati Venu Resigns As MD (Feb 18)

* AMBATI VENU RESIGNS AS MANAGING DIRECTOR Source text for Eikon: Further company coverage:

BRIEF-Abbott India's Dec-Quarter Profit Rises

* DEC-QUARTER PROFIT 1.87 BILLION RUPEES VERSUS 1.17 BILLION RUPEES YEAR AGO

BRIEF-Abbott India Dec-Qtr Net Profit Rises

* DEC QUARTER NET PROFIT 1.15 BILLION RUPEES VERSUS PROFIT 855.6 MILLION RUPEES YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up